NCT01074125 - A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease | Biotech Hunter

Enrollment

154

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

HyperphosphatemiaEnd-Stage Renal Disease

Interventions

DRUG

ferric citrate

1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days

Trial Locations (16)

11212

Brookdale Physician's Dialysis Associates, Brooklyn

30901

Kidney Care Associates, LLC, Augusta

33028

Pines Clinical Research, Inc., Pembroke Pines

37205

Nephrology Associates, PC, Nashville

37208

Meharry Medical College Clinical Research Center, Nashville

37404

Southeast Renal Research Institute, Chattanooga

43210

The Ohio State University Cramblett Medical Clinic, Columbus

44104

Cleveland Clinical Foundation Fresenius East (Fairhill), Cleveland

45206

DCI, Cincinnati

53214

Centre Point Dialysis, West Allis

60607

Circle Medical Management, Chicago

77030

Kidney Associates, Houston

80031

Western Nephrology, Westminster

01107

Western New England Renal & Transplant Associates, Springfield

37232-1371

Vanderbilt University Medical Center Clinical Trials Center, Nashville

00936-5067

RCMI- Clinical Research Center Medical Sciences Campus University of Puerto Rico, Rio Piedras